Connecting to LinkedIn...

W1siziisijiwmtuvmdqvmtuvmdgvntqvmzgvnzi1l01ptlrbu0hfqkxpr19vtljftkrfukvex0lnqudfx3jlc2l6zwrfyw5kx3jlbmrlcmvklmpwzyjdlfsiccisinrodw1iiiwimtkymhgxmjuwiyjdxq

Blog

Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Dravet Syndrome, a Rare Form of Epilepsy

2/07/2014 by

W1siziisijiwmtqvmtavmjgvmtuvmzqvntavmtivzmlszsjdlfsiccisinrodw1iiiwinjawedqwmfx1mdazzsjdxq

Insys Therapeutics, Inc., a specialty pharmaceutical company that is developing and commercialising innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its pharmaceutical cannabidiol (CBD) for the treatment of Dravet syndrome, a rare pediatric-onset epilepsy.

“There is presently no cure for this catastrophic form of epilepsy, and the significant, unmet need is recognised by the orphan drug designation we received today for our pharmaceutical CBD,” said Michael L. Babich, President and Chief Executive Officer. “Our pharmaceutical CBD is an alternative to plant derived cannabinoids, one which we believe will provide significant medical benefits and better address the unmet needs of patients across multiple indications including Dravet syndrome. We expect to file an Investigational New Drug Application (IND) for CBD in the second half of 2014.”

Insys has more than seven years of research and development experience in the pharmaceutical cannabinoid space. The company manufactures pharmaceutical dronabinol (THC) and pharmaceutical CBD, both of which are cannabinoids, at its FDA-inspected and Drug Enforcement Administration (DEA) approved facility in Round Rock, Texas. Insys believes it is the only U.S.-based company with the capacity to produce pharmaceutical cannabinoids in scalable quantities.

This article has been extracted from http://www.marketwatch.com, please click on this link to read the article in full http://www.marketwatch.com/story/insys-therapeutics-receives-fda-orphan-drug-designation-for-its-pharmaceutical-cannabidiol-as-a-potential-treatment-for-dravet-syndrome-a-rare-form-of-epilepsy-2014-07-02

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

comments powered by Disqus

Social Stream

Latest News

W1siziisijiwmtyvmtivmdcvmtavmdyvndkvntg0l0vudgvychjpc2ugcmvzb3vyy2ugcgxhbm5pbmcgy29wes5qcgcixsxbinailcj0ahvtyiisijm4mhgxmdajil1d

Infor launches new mobile solution

2016-12-07 09:00:00 +0000

Infor, one of the global leaders in enterprise resource planning (ERP) software, has revealed that it is launching a new mobile solution. The company, which has focused on developing specialised business applications for a variety of industries, unveiled Infor Mobility for Field Service (MFS). The solution is a comprehensive mobility application that can streamline operations for employees working in the field. To ensure that field technicians are provi...

W1siziisijiwmtyvmtivmdyvmdkvmjcvmtavnze4l2nsb3vkihrly2hub2xvz3kgc2vydmljzxmuanbnil0swyjwiiwidgh1bwiilcizodb4mtawiyjdxq

AI continues to infiltrate cloud computing se...

2016-12-06 09:00:00 +0000

With Google and Microsoft both already working on artificial intelligence (AI) software for their cloud services, it has been revealed that Amazon is now to join the battle. The internet giant is to prioritise developing AI for Amazon Web Services (AWS), the division that sells data storage and computing to IT professionals around the world. AWS is currently the fastest-growing division for Amazon, with the past year having seen sales soar by 60 per cen...